Medica Venture Partners

Medica concentrates exclusively on healthcare — medical devices, biotech, and digital health — out of Herzliya, Israel. The firm backs early-stage and growth-stage companies, predominantly Israeli-founded, that target FDA clearance and US commercialization. This sector specialization is unusual among Israeli VCs, which more commonly pursue cybersecurity, enterprise software, and general tech.

Notable exits include MediGuide, an intrabody navigation technology acquired by St. Jude Medical; SuperDimension, a bronchoscopic navigation company acquired by Covidien, now part of Medtronic; and EndoChoice, a GI imaging platform that listed on the NYSE before its acquisition by Boston Scientific. These exits span cardiovascular, pulmonary, and gastroenterology device segments.

Yes, Medica has historically co-invested alongside US-based healthcare specialist VCs. This co-investment pattern helps Israeli portfolio companies establish relationships with US strategic acquirers, which is critical for life-science startups that typically seek FDA clearance and North American distribution.

Most Israeli venture firms are generalist, with heavy exposure to cybersecurity, enterprise software, and AI. Medica is a pure-play healthcare investor. This concentration gives it a sourcing advantage inside Israeli hospitals and research institutions, where competition from generalist VCs is thinner and domain expertise matters for technical diligence.

The firm's portfolio companies have obtained FDA clearance across multiple device categories, including cardiovascular navigation, bronchoscopic guidance, and GI imaging. Specific approvals are tied to individual portfolio companies and their US commercial strategies, with exits to strategics like Medtronic and Boston Scientific validating the regulatory pathway.